Bottom line
How much do PHSYX and ETHSX overlap?
71% of their top holdings overlap by weight. 16 securities appear in both funds' top 25, making up 73.9% of PHSYX's assets and 72.6% of ETHSX's. They are largely the same portfolio — owning both adds little diversification.
PHSYX holds far more positions (115 vs 42), so it is broader beyond the top names.
Updated Nov 22, 2026
Overlap at a glance
Holdings PHSYX and ETHSX have in common
| Holding | % of PHSYX | % of ETHSX | Overlap |
|---|---|---|---|
| Eli Lilly & Co. | 13.15% | 12.47% | 12.47% |
| Johnson & Johnson | 8.46% | 6.45% | 6.45% |
| UnitedHealth Group, Inc. | 6.93% | 5.49% | 5.49% |
| AbbVie, Inc. | 6.05% | 6.46% | 6.05% |
| Novartis AG | 5.13% | 1.65% | 1.65% |
| Merck & Co., Inc. | 4.88% | 5.08% | 4.88% |
| AstraZeneca plc | 4.67% | 6.24% | 4.67% |
| Thermo Fisher Scientific, Inc. | 4.50% | 2.79% | 2.79% |
| Intuitive Surgical, Inc. | 4.04% | 2.72% | 2.72% |
| Sanofi SA | 3.23% | 2.95% | 2.95% |
| Roche Holding AG | 2.79% | 5.44% | 2.79% |
| Gilead Sciences, Inc. | 2.63% | 3.34% | 2.63% |
| Vertex Pharmaceuticals, Inc. | 1.97% | 3.38% | 1.97% |
| Novo Nordisk A/S | 1.90% | 1.71% | 1.71% |
| Boston Scientific Corp. | 1.80% | 2.18% | 1.80% |
| Bristol-Myers Squibb Co. | 1.75% | 4.25% | 1.75% |
Source: SEC Form N-PORT (periods May 31, 2026 / May 31, 2026)
Free weekly newsletter
The Fund Letter
Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.
Free. Unsubscribe anytime. We never sell your email.
What each fund holds that the other doesn't
Top-25 holdings that appear in only one of the two funds' top 25.
Only in PHSYX
- Edwards Lifesciences Corp. — 2.80%
- CVS Health Corp. — 2.74%
- McKesson Corp. — 2.14%
- Cardinal Health, Inc. — 2.12%
- Dexcom, Inc. — 1.64%
- Hoya Corp. — 1.52%
- Putnam Short Term Investment Fund — 1.35%
- HCA Healthcare, Inc. — 1.18%
- Amgen, Inc. — 1.11%
Only in ETHSX
- Stryker Corp — 2.21%
- Medtronic PLC — 1.80%
- Lonza Group AG — 1.77%
- Abbott Laboratories — 1.65%
- Argenx SE — 1.61%
- Royalty Pharma PLC — 1.58%
- Neurocrine Biosciences Inc — 1.41%
- Mettler-Toledo International Inc — 1.36%
- Straumann Holding AG — 1.34%
Asset mix
| Asset type | PHSYX | ETHSX |
|---|---|---|
| Stocks | 98.2% | 99.4% |
| Other | 1.4% | — |
| Cash & short-term funds | 0.6% | 0.3% |
Source: SEC Form N-PORT (periods May 31, 2026 / May 31, 2026)
Country mix
| Country | PHSYX | ETHSX |
|---|---|---|
| US | 76.2% | 69.4% |
| CH | 7.9% | 10.2% |
| GB | 6.4% | 7.8% |
| FR | 3.2% | 3.2% |
| DK | 2.4% | 2.9% |
| JP | 2.4% | — |
| NL | 1.2% | 2.0% |
| IE | — | 1.8% |
Source: SEC Form N-PORT (periods May 31, 2026 / May 31, 2026)
Check another pair
FAQ
How much do PHSYX and ETHSX overlap?
What stocks do PHSYX and ETHSX have in common?
Should I own both PHSYX and ETHSX?
Which holds more stocks, PHSYX or ETHSX?
Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.